Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor-Reference-Cited by-同舟云学术

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

Published:2015-09 Issue:9 Volume:10 Page:1292-1300
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Yeung Sai F.,Tong Joanna H.M.,Law Peggy P.W.,Chung Lau Y.,Lung Raymond W.M.,Tong Carol Y.K.,Chow Chit,Chan Anthony W.H.,Wan Innes Y.P.,Mok Tony S.K.,To Ka F.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

3. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib;Ignatius Ou;J Thorac Oncol,2014

4. Ceritinib in ALK-rearranged non-small-cell lung cancer;Shaw;N Engl J Med,2014

5. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology;Lung Cancer;2024-10

2. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations;European Journal of Cancer;2024-08

3. Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study;Journal of Clinical Oncology;2024-07-26

4. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant;Pathology;2024-06

5. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target;Cancers;2023-09-28